The ESCMID Study Group for Clostridioides difficile: History, Role, and Perspectives

Adv Exp Med Biol. 2024:1435:351-362. doi: 10.1007/978-3-031-42108-2_16.

Abstract

Clostridioides difficile (C. difficile) is a major nosocomial pathogen but is also increasingly recognised as an important diarrhoeal pathogen in the community, not always associated with antibiotics. The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for C. difficile (ESGCD) is a group of clinicians, scientists, and others from many European countries and further afield, who share a common interest in C. difficile. The aims of the Study Group are centred around raising the profile of C. difficile infection (CDI) in humans and animals, fostering collaboration amongst centres in different European countries and providing a forum for discussing and disseminating information. One of the principal aims of the Study Group is to raise awareness of C. difficile infections in Europe. ESGCD has a particular interest in the development and dissemination of European guidance on prevention, diagnosis, and treatment of CDI. This chapter will discuss the organisation of ESGCD within the ESCMID Study Group structure, the origins of the Study Group, the aims, and objectives of the group, and will highlight some of the past and present activities of ESGCD in relation to these.

Keywords: C. difficile guidelines; C. difficile research; ESCMID; Research projects.

MeSH terms

  • Animals
  • Anti-Bacterial Agents / therapeutic use
  • Clostridioides difficile*
  • Communicable Diseases*
  • Diarrhea
  • Europe / epidemiology
  • Humans

Substances

  • Anti-Bacterial Agents